Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested Capital

Spyre Therapeutics (SYRE) Return on Invested Capital (2022 - 2025)

Spyre Therapeutics (SYRE) has disclosed Return on Invested Capital for 4 consecutive years, with 0.35% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Return on Invested Capital rose 12.0% year-over-year to 0.35%, compared with a TTM value of 0.35% through Dec 2025, up 12.0%, and an annual FY2025 reading of 0.33%, up 25.0% over the prior year.
  • Return on Invested Capital was 0.35% for Q4 2025 at Spyre Therapeutics, up from 0.44% in the prior quarter.
  • Across five years, Return on Invested Capital topped out at 46.24% in Q2 2023 and bottomed at 1.88% in Q1 2023.
  • Average Return on Invested Capital over 4 years is 3.11%, with a median of 0.47% recorded in 2024.
  • The sharpest move saw Return on Invested Capital soared 4744bps in 2023, then plummeted -4682bps in 2024.
  • Year by year, Return on Invested Capital stood at 1.44% in 2022, then skyrocketed by 743bps to 9.23% in 2023, then tumbled by -105bps to 0.47% in 2024, then grew by 25bps to 0.35% in 2025.
  • Business Quant data shows Return on Invested Capital for SYRE at 0.35% in Q4 2025, 0.44% in Q3 2025, and 0.41% in Q2 2025.